Trial Profile
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Apr 2022
Price :
$35
*
At a glance
- Drugs KA 2237 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Sponsors Karus Therapeutics
- 04 Dec 2019 According to Karus Therapeutics media release, new data will be presented from this study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019.
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 04 Feb 2019 Status changed from recruiting to completed.